Herpes Zoster Vaccination in Systemic Lupus Erythematosus: the Current Status

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2018 Aug 22

PMID 30130445

Citations 11

Authors

Chi Chiu Mok

Affiliations

Soon will be listed here.

Abstract

Among the inflammatory rheumatic diseases, SLE is associated with the highest risk of herpes zoster reactivation relative to age. The reported incidence of herpes zoster infection in SLE ranges from 6.4 to 91.4/1000 patient-years, with main risk factors being major organ disease, immunosuppressive and biological therapies. Although herpes zoster in SLE is manageable with anti-viral treatment, complications such as superimposed bacterial infection, post-herpetic neuralgia may ensue. The low rate of herpes zoster vaccination in SLE is related to the lack of awareness, fear of the risk of vaccine-induced infection and disease flare, cost, as well as the lack of explicit recommendations of vaccine use for the paucity of data in immunocompromised and younger subjects. The recent availability of the non-live subunit and inactivated herpes zoster vaccines has provided more opportunities for SLE patients to be protected against this viral infection. More clinical trials are clearly needed in SLE to confirm safety, immunogenicity and efficacy of the herpes zoster vaccines.

Citing Articles

A Framework to Overcome Challenges in the Management of Infections in Patients with Systemic Lupus Erythematosus.

Rao M, Mikdashi J Open Access Rheumatol. 2023; 15:125-137.

PMID: 37534019 PMC: 10391536. DOI: 10.2147/OARRR.S295036.

Factors and Reasons for Non-vaccination among Patients with Systemic Lupus Erythematosus: A Single-centre, Cross-sectional Study.

Miyake H, Minoda Sada R, Manabe A, Tsugihashi Y, Hatta K Intern Med. 2022; 62(17):2483-2491.

PMID: 36575017 PMC: 10518547. DOI: 10.2169/internalmedicine.1067-22.

Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.

Mok C, Ho L, Tse S, Chan K, To C Clin Rheumatol. 2022; 42(4):1019-1026.

PMID: 36385600 DOI: 10.1007/s10067-022-06450-2.

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.

Liu Z, Cheng R, Liu Y Front Immunol. 2022; 13:996662.

PMID: 36211347 PMC: 9537685. DOI: 10.3389/fimmu.2022.996662.

Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study.

Wang H, Zhou Y, Yu L, Wu W, Zhao L, Geng S Lupus Sci Med. 2022; 9(1).

PMID: 36041813 PMC: 9438011. DOI: 10.1136/lupus-2022-000725.

References

Moutsopoulos H, Gallagher J, Decker J, Steinberg A . Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum. 1978; 21(7):798-802. DOI: 10.1002/art.1780210710. View

Harpaz R, Ortega-Sanchez I, Seward J . Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57(RR-5):1-30. View

Lal H, Cunningham A, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015; 372(22):2087-96. DOI: 10.1056/NEJMoa1501184. View

Levin M, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw K, Willis E . Studies with herpes zoster vaccines in immune compromised patients. Expert Rev Vaccines. 2017; 16(12):1217-1230. DOI: 10.1080/14760584.2017.1395703. View

Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley J . Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol. 2016; 68(9):2328-37. PMC: 5396838. DOI: 10.1002/art.39670. View

Berkowitz E, Moyle G, Stellbrink H, Schurmann D, Kegg S, Stoll M . Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2014; 211(8):1279-87. PMC: 4371767. DOI: 10.1093/infdis/jiu606. View

Khamashta M, Merrill J, Werth V, Furie R, Kalunian K, Illei G . Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75(11):1909-1916. PMC: 5099191. DOI: 10.1136/annrheumdis-2015-208562. View

Zhang J, Xie F, Delzell E, Chen L, Winthrop K, Lewis J . Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012; 308(1):43-9. PMC: 3683869. DOI: 10.1001/jama.2012.7304. View

Lee P, Lee T, Ho M, Wong W, Lau Y . Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors. Pediatr Infect Dis J. 2006; 25(8):728-32. DOI: 10.1097/01.inf.0000226841.03751.1f. View

10.

Schmader K, Levin M, Gnann Jr J, McNeil S, Vesikari T, Betts R . Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012; 54(7):922-8. PMC: 4542655. DOI: 10.1093/cid/cir970. View

11.

van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran M, Dougados M . EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2010; 70(3):414-22. DOI: 10.1136/ard.2010.137216. View

12.

Cunningham A, Lal H, Kovac M, Chlibek R, Hwang S, Diez-Domingo J . Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016; 375(11):1019-32. DOI: 10.1056/NEJMoa1603800. View

13.

Cohen J . Clinical practice: Herpes zoster. N Engl J Med. 2013; 369(3):255-63. PMC: 4789101. DOI: 10.1056/NEJMcp1302674. View

14.

Willis E, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato P . Herpes zoster vaccine live: A 10 year review of post-marketing safety experience. Vaccine. 2017; 35(52):7231-7239. PMC: 5739308. DOI: 10.1016/j.vaccine.2017.11.013. View

15.

Furie R, Khamashta M, Merrill J, Werth V, Kalunian K, Brohawn P . Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2):376-386. PMC: 5299497. DOI: 10.1002/art.39962. View

16.

Freer G, Pistello M . Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018; 41(2):95-105. View

17.

Doan H, Ung B, Ramirez-Fort M, Khan F, Tyring S . Zostavax : a subcutaneous vaccine for the prevention of herpes zoster. Expert Opin Biol Ther. 2013; 13(10):1467-77. DOI: 10.1517/14712598.2013.830101. View

18.

Kang I, Park S . Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003; 15(5):528-34. DOI: 10.1097/00002281-200309000-00002. View

19.

Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H . High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis. 1990; 49(8):630-3. PMC: 1004180. DOI: 10.1136/ard.49.8.630. View

20.

Winston D, Mullane K, Cornely O, Boeckh M, Brown J, Pergam S . Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10135):2116-2127. DOI: 10.1016/S0140-6736(18)30631-7. View